You are here: Industry Insights > Solid Tumors

News List

Harpoon files $86M IPO to help fund its T-cell engager platform fiercebiotech
January 04, 2019
Fresh off raising $70 million through a series C round just over a month ago, Harpoon Therapeutics announced it will go public with an $86.25 million IPO to further support its portfolio of early-stage T-cell engagers aimed at solid tumors.....
F1 Oncology Expands Operations contractpharma
November 18, 2018
Shanghai EXUMA will develop these clinical programs into multicenter trials under a centralized regulatory pathway based on the results of investigator-initiated trials (IITs) of CAR-T therapies for the treatment of metastatic renal cell carcinoma (mRCC)
Glenmark Launches CD38xCD3 Phase 1 Trial for Bispecific Antibody GBR 1342 americanpharmaceuticalreview
November 10, 2018
Glenmark Pharmaceuticals announced the decision to launch a Phase 1 trial in solid tumors for its CD38xCD3 bispecific antibody GBR 1342. The decision is driven by recent findings derived from a non-interventional human study utilizing a clinically validat
Bristol-Myers Squibb and Compugen announce clinical collaboration to evaluate therapeutic regimen in advanced solid tumors worldpharmanews
October 12, 2018
Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen's COM701, an investigational anti-PVRIG antibody, in co
Apexian Pharmaceuticals Opens Phase I Clinical Study of APX3330 in Patients with Solid Tumors biospace
January 25, 2018
Apexian Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has announced the opening of a clinical trial for patients with advanced solid tumors.

Previous page 1 2 3 Next page